OptimizeRx (NASDAQ:OPRX) Given New $10.00 Price Target at Stephens

OptimizeRx (NASDAQ:OPRX) had its price objective decreased by Stephens from $17.00 to $10.00 in a report issued on Friday morning,Benzinga reports. Stephens currently has an equal weight rating on the stock.

Several other brokerages have also commented on OPRX. Citizens Jmp increased their price objective on OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Zacks Research lowered OptimizeRx from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 15th. Wall Street Zen upgraded OptimizeRx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 14th. Weiss Ratings reissued a “sell (d+)” rating on shares of OptimizeRx in a report on Monday, December 22nd. Finally, Stifel Nicolaus cut their price objective on shares of OptimizeRx from $21.00 to $17.00 and set a “buy” rating on the stock in a report on Friday. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, OptimizeRx has a consensus rating of “Moderate Buy” and a consensus target price of $17.57.

OptimizeRx Stock Down 10.5%

Shares of NASDAQ OPRX traded down $0.79 during trading hours on Friday, hitting $6.74. 2,099,710 shares of the stock were exchanged, compared to its average volume of 437,141. OptimizeRx has a 12 month low of $3.99 and a 12 month high of $22.25. The firm has a fifty day moving average price of $10.52 and a 200-day moving average price of $14.73. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 0.20. The company has a market cap of $125.63 million, a PE ratio of 25.92 and a beta of 1.20.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Saturday, January 31st. The company reported $0.51 earnings per share for the quarter. OptimizeRx had a net margin of 4.69% and a return on equity of 10.81%. On average, sell-side analysts expect that OptimizeRx will post -0.33 EPS for the current year.

OptimizeRx announced that its board has approved a stock buyback program on Thursday, March 5th that authorizes the company to buyback $10.00 million in shares. This buyback authorization authorizes the company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its stock is undervalued.

Hedge Funds Weigh In On OptimizeRx

Hedge funds have recently made changes to their positions in the company. CenterBook Partners LP acquired a new stake in OptimizeRx during the 3rd quarter worth about $6,331,000. Next Century Growth Investors LLC lifted its holdings in shares of OptimizeRx by 139.8% during the fourth quarter. Next Century Growth Investors LLC now owns 505,407 shares of the company’s stock worth $6,196,000 after purchasing an additional 294,688 shares during the period. Manatuck Hill Partners LLC boosted its position in OptimizeRx by 139.5% in the second quarter. Manatuck Hill Partners LLC now owns 455,000 shares of the company’s stock valued at $6,142,000 after buying an additional 265,000 shares during the last quarter. Kennedy Capital Management LLC boosted its position in OptimizeRx by 42.8% in the third quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company’s stock valued at $13,836,000 after buying an additional 202,446 shares during the last quarter. Finally, Invesco Ltd. acquired a new position in OptimizeRx in the 3rd quarter worth approximately $4,081,000. 76.47% of the stock is owned by institutional investors and hedge funds.

Key OptimizeRx News

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 earnings and revenue beat expectations — OPRX reported stronger-than-expected results (EPS and revenue topped consensus), supporting the company’s underlying growth narrative. Q4 Results
• Positive Sentiment: Board authorized a $10.0M share repurchase program (up to ~6.8% of shares), a shareholder-friendly move that typically supports share price over time by reducing float. Buyback Announcement
• Neutral Sentiment: Roth MKM lowered its price target from $32 to $18 but kept a “buy” rating — still a materially higher target than current levels, creating mixed signals (cut in optimism but continued buy conviction). Roth MKM PT Change
• Neutral Sentiment: Multiple brief trading halts for OPRX were reported today due to LULD pauses — technical market safeguards that can amplify volatility but do not convey fundamental news.
• Negative Sentiment: FY2026 revenue guidance came in at $109M–$114M versus consensus near $122M — a notable shortfall that likely drove investor disappointment and downward pressure on the stock. Guidance Story
• Negative Sentiment: B. Riley reaffirmed its buy rating but cut its price target from $28 to $11 — another analyst reduction that removes prior upside and likely contributed to selling pressure. B. Riley PT Cut
• Negative Sentiment: Stephens trimmed its target to $10 and set an “equal weight” rating, signaling a more cautious view and reducing analyst-driven upside expectations. Stephens PT Change

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.